cell-free DNA in plasma for colorectal cancer screening; Shield DNA test
Jump to navigation
Jump to search
Indications
- screening for colorectal cancer
- cell-free DNA detects 88% of stage 1,2, & 3 colorectal cancers[1]
- only detects 13% of precancerous lesions
- false positives 10%
- Guardant's Shield test (FDA-approved) detects 83% of colorectal cancers[1]
- cell-free DNA detects 88% of stage 1,2, & 3 colorectal cancers[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Chung DC, Gray DM II, Singh H et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med 2024 Mar 14; 390:973 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38477985 https://www.nejm.org/doi/10.1056/NEJMoa2304714
Reuters Health Information, July 29, 2024 US FDA Approves Guardant Health's Blood-based Cancer Test. https://www.medscape.com/s/viewarticle/us-fda-approves-guardant-healths-blood-based-cancer-test-2024a1000duo - ↑ Zhao F, Bai P, Xu J, Li Z, Muhammad S, Li D, Zhang Z, Gao Y, Liu Q. Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study. Mol Cancer. 2023 Sep 28;22(1):157. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37770864 PMCID: PMC10538018 Free PMC article.